| pubmed-article:8557989 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8557989 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8557989 | lifeskim:mentions | umls-concept:C0330390 | lld:lifeskim |
| pubmed-article:8557989 | lifeskim:mentions | umls-concept:C1513095 | lld:lifeskim |
| pubmed-article:8557989 | lifeskim:mentions | umls-concept:C1721046 | lld:lifeskim |
| pubmed-article:8557989 | lifeskim:mentions | umls-concept:C0542341 | lld:lifeskim |
| pubmed-article:8557989 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:8557989 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:8557989 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:8557989 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8557989 | pubmed:dateCreated | 1996-2-27 | lld:pubmed |
| pubmed-article:8557989 | pubmed:abstractText | The chemokine GRO alpha is an autocrine growth factor for melanoma cells. Although GRO alpha has been identified as a high affinity ligand for the IL-8 receptor beta (IL-8R beta) in recombinant systems, the receptor mediating its action in melanoma cells has been a matter of debate. Here, we show by reverse transcription and PCR expression of IL-8R beta, mRNA transcripts in different melanoma cell lines and in normal human melanocytes. To characterize the role of the IL-8R beta in melanoma cells, antiserum was raised in rabbits against a fusion protein containing the NH2-terminal portion of the receptor. Its specificity was shown by flow cytometry with IL-8R beta-transfected HL60 cells. A specific epitope could be mapped with IL-8R beta mutants to the peptide sequence between ASP-4 and ASP-14 of this receptor. Binding studies with [125I]GRO alpha in IL-8R beta transfectants indicated ligand antagonistic properties of this Ab. Expression of IL-8R beta protein at the cell surface of various melanoma cell lines could be shown by flow cytometry with F(ab')2 fragments of the IL-8R beta antiserum. Moreover, anti-IL-8R beta Ab partially blocked specific binding of [125I]GRO alpha in various melanoma cell lines. Addition of F(ab')2 fragments of the IL-8R beta antiserum or of neutralizing anti-GRO alpha mAb to different melanoma cell lines identified this GRO alpha-IL-8R beta interaction as a major component required for serum-independent melanoma cell growth. | lld:pubmed |
| pubmed-article:8557989 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8557989 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8557989 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8557989 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:8557989 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:8557989 | pubmed:author | pubmed-author:NorgauerJJ | lld:pubmed |
| pubmed-article:8557989 | pubmed:author | pubmed-author:MetznerBB | lld:pubmed |
| pubmed-article:8557989 | pubmed:author | pubmed-author:Schraufstätte... | lld:pubmed |
| pubmed-article:8557989 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8557989 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8557989 | pubmed:volume | 156 | lld:pubmed |
| pubmed-article:8557989 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8557989 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8557989 | pubmed:pagination | 1132-37 | lld:pubmed |
| pubmed-article:8557989 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:meshHeading | pubmed-meshheading:8557989-... | lld:pubmed |
| pubmed-article:8557989 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8557989 | pubmed:articleTitle | Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. | lld:pubmed |
| pubmed-article:8557989 | pubmed:affiliation | Clinic of Dermatology, University of Freiburg, Germany. | lld:pubmed |
| pubmed-article:8557989 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8557989 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8557989 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8557989 | lld:pubmed |
